Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Executive Summary
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.
You may also be interested in...
Record Revenues For Takeda But Headwinds Coming
While Japan's largest pharma company reached a number of milestones last fiscal year, it is facing a number of challenges to revenues in 2023, for which it is looking to its core commercial portfolio and pipeline to help drive growth.
Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor
Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.